FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3086689908> ?p ?o ?g. }

• W3086689908 endingPage "2935" @default.
• W3086689908 startingPage "2935" @default.
• W3086689908 abstract "The ongoing coronavirus disease 2019 (COVID-19) pandemic has resulted in efforts to identify therapies to ameliorate adverse clinical outcomes. The recognition of the key role for increased inflammation in COVID-19 has led to a proliferation of clinical trials targeting inflammation. The purpose of this review is to characterize the current state of immunotherapy trials in COVID-19, and focuses on associated cardiotoxicities, given the importance of pharmacovigilance. The search terms related to COVID-19 were queried in ClinicalTrials.gov. A total of 1621 trials were identified and screened for interventional trials directed at inflammation. Trials (n = 226) were fully assessed for the use of a repurposed drug, identifying a total of 141 therapeutic trials using a repurposed drug to target inflammation in COVID-19 infection. Building on the results of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial demonstrating the benefit of low dose dexamethasone in COVID-19, repurposed drugs targeting inflammation are promising. Repurposed drugs directed at inflammation in COVID-19 primarily have been drawn from cancer therapies and immunomodulatory therapies, specifically targeted anti-inflammatory, anti-complement, and anti-rejection agents. The proposed mechanisms for many cytokine-directed and anti-rejection drugs are focused on evidence of efficacy in cytokine release syndromes in humans or animal models. Anti-complement-based therapies have the potential to decrease both inflammation and microvascular thrombosis. Cancer therapies are hypothesized to decrease vascular permeability and inflammation. Few publications to date describe using these drugs in COVID-19. Early COVID-19 intervention trials have re-emphasized the subtle, but important cardiotoxic sequelae of potential therapies on outcomes. The volume of trials targeting the COVID-19 hyper-inflammatory phase continues to grow rapidly with the evaluation of repurposed drugs and late-stage investigational agents. Leveraging known clinical safety profiles and pharmacodynamics allows swift investigation in clinical trials for a novel indication. Physicians should remain vigilant for cardiotoxicity, often not fully appreciated in small trials or in short time frames." @default.
• W3086689908 created "2020-09-21" @default.
• W3086689908 creator A5044991433 @default.
• W3086689908 creator A5057426360 @default.
• W3086689908 creator A5065015589 @default.
• W3086689908 creator A5085150089 @default.
• W3086689908 creator A5087164932 @default.
• W3086689908 date "2020-09-11" @default.
• W3086689908 modified "2023-10-14" @default.
• W3086689908 title "Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review" @default.
• W3086689908 cites W1533986220 @default.
• W3086689908 cites W1546689286 @default.
• W3086689908 cites W1783019770 @default.
• W3086689908 cites W1829587101 @default.
• W3086689908 cites W1973378701 @default.
• W3086689908 cites W1980204384 @default.
• W3086689908 cites W1982520530 @default.
• W3086689908 cites W1996341114 @default.
• W3086689908 cites W2000536536 @default.
• W3086689908 cites W2007386646 @default.
• W3086689908 cites W2014413066 @default.
• W3086689908 cites W2017281076 @default.
• W3086689908 cites W2021223904 @default.
• W3086689908 cites W2026602389 @default.
• W3086689908 cites W2036879623 @default.
• W3086689908 cites W2037881603 @default.
• W3086689908 cites W2039027344 @default.
• W3086689908 cites W2047608359 @default.
• W3086689908 cites W2049902839 @default.
• W3086689908 cites W2054076340 @default.
• W3086689908 cites W2054220445 @default.
• W3086689908 cites W2054318449 @default.
• W3086689908 cites W2059209526 @default.
• W3086689908 cites W2060140838 @default.
• W3086689908 cites W2063260802 @default.
• W3086689908 cites W2064466723 @default.
• W3086689908 cites W2104730008 @default.
• W3086689908 cites W2105957247 @default.
• W3086689908 cites W2110715762 @default.
• W3086689908 cites W2112687224 @default.
• W3086689908 cites W2114702694 @default.
• W3086689908 cites W2115859409 @default.
• W3086689908 cites W2120801007 @default.
• W3086689908 cites W2129542667 @default.
• W3086689908 cites W2130450914 @default.
• W3086689908 cites W2132918724 @default.
• W3086689908 cites W2134270225 @default.
• W3086689908 cites W2154268960 @default.
• W3086689908 cites W2166569409 @default.
• W3086689908 cites W2177407033 @default.
• W3086689908 cites W2179903488 @default.
• W3086689908 cites W2208498818 @default.
• W3086689908 cites W2240913867 @default.
• W3086689908 cites W2275001939 @default.
• W3086689908 cites W2325322965 @default.
• W3086689908 cites W2326205797 @default.
• W3086689908 cites W2340435799 @default.
• W3086689908 cites W2417998419 @default.
• W3086689908 cites W2464293395 @default.
• W3086689908 cites W2520543291 @default.
• W3086689908 cites W2528174730 @default.
• W3086689908 cites W2563793305 @default.
• W3086689908 cites W2590932802 @default.
• W3086689908 cites W2601742683 @default.
• W3086689908 cites W2609086478 @default.
• W3086689908 cites W2620823272 @default.
• W3086689908 cites W2746724707 @default.
• W3086689908 cites W2748400555 @default.
• W3086689908 cites W2757190301 @default.
• W3086689908 cites W2757527323 @default.
• W3086689908 cites W2769689735 @default.
• W3086689908 cites W2786515668 @default.
• W3086689908 cites W2789315292 @default.
• W3086689908 cites W2794403789 @default.
• W3086689908 cites W2795353688 @default.
• W3086689908 cites W2796022095 @default.
• W3086689908 cites W2806521568 @default.
• W3086689908 cites W2808166290 @default.
• W3086689908 cites W2811067466 @default.
• W3086689908 cites W2887108385 @default.
• W3086689908 cites W2887577080 @default.
• W3086689908 cites W2897515101 @default.
• W3086689908 cites W2898080189 @default.
• W3086689908 cites W2901478468 @default.
• W3086689908 cites W2908053584 @default.
• W3086689908 cites W2917639850 @default.
• W3086689908 cites W2919640907 @default.
• W3086689908 cites W2921937828 @default.
• W3086689908 cites W2965379348 @default.
• W3086689908 cites W2965453023 @default.
• W3086689908 cites W2966093740 @default.
• W3086689908 cites W2972293235 @default.
• W3086689908 cites W2973341403 @default.
• W3086689908 cites W2974630541 @default.
• W3086689908 cites W2976249548 @default.
• W3086689908 cites W2978550355 @default.
• W3086689908 cites W2979113883 @default.
• W3086689908 cites W2988255546 @default.

• next